Sarra El-Abed
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024
Mar 28, 2024Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Mar 28, 2024JAMA Oncol 2024
Fernandez-Martinez Aranzazu, Rediti Mattia, Tang Gong, Pascual Tomás, Hoadley Katherine A, Venet David, Rashid Naim U, Spears Patricia A, Islam N, El-Abed Sarra, Bliss Judith, Lambertini Matteo, Di Cosimo Serena, Huober Jens, Goerlitz David, Hu Rong, Lucas Peter C, Swain Sandra M, Sotiriou Christos, Perou Charles M, Carey Lisa A
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol 2023; 12:1028825.
Jan 31, 2023End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Jan 31, 2023Front Oncol 2023; 12:1028825
Di Cosimo Serena, Ciniselli Chiara M, Pizzamiglio Sara, Cappelletti Vera, Silvestri Marco, El-Abed Sarra, Izquierdo Miguel, Bajji Mohammed, Nuciforo Paolo, Huober Jens, Cameron David, Chia Stephen, Gomez Henry L, Iorio Marilena V, Vingiani Andrea, Pruneri Giancarlo, Verderio Paolo
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022; 181:92-101.
Dec 27, 2022Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Dec 27, 2022Eur J Cancer 2022; 181:92-101
Nuciforo Paolo, Townend John, Piccart Martine, Fielding Shona, Gkolfi Panagiota, El-Abed Sarra, de Azambuja Evandro, Werutsky Gustavo, Bliss Judith, Moebus Volker, Colleoni Marco, Aspitia Alvaro Moreno, Gomez Henry, Gombos Andrea, Coccia-Portugal Maria Antonia, Tseng Ling-Ming, Kunz Georg, Lerzo Guillermo, Sohn Joohyuk, Semiglazov Vladimir, Saura Cristina, Kroep Judith, Ferro Antonella, Cameron David, Gelber Richard D, Huober Jens, Di Cosimo Serena
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
Ligorio F, Huober J, Moscetti L, Janni W, Coccia-Portugal M, Corsetto P, Belfiore A, Lorenzini D, Daidone M, Vingiani A, Gianni L, Pupa S, Bianchini G, Pruneri G, Nuciforo P, de Azambuja E, Izquierdo M, Di Cosimo S, Verderio P, Ciniselli C, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Vernieri C. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. J Natl Cancer Inst 2022
Jul 5, 2022Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
Jul 5, 2022J Natl Cancer Inst 2022
Ligorio Francesca, Huober Jens, Moscetti Luca, Janni Wolfgang, Coccia-Portugal Maria Antonia, Corsetto Paola Antonia, Belfiore Antonino, Lorenzini Daniele, Daidone Maria Grazia, Vingiani Andrea, Gianni Luca, Pupa Serenella Maria, Bianchini Giampaolo, Pruneri Giancarlo, Nuciforo Paolo, de Azambuja Evandro, Izquierdo Miguel, Di Cosimo Serena, Verderio Paolo, Ciniselli Chiara Maura, Pizzamiglio Sara, Castagnoli Lorenzo, Dugo Matteo, Galbardi Barbara, Salgado Roberto, Loi Sherene, Michiels Stefan, Triulzi Tiziana, Tagliabue Elda, El-Abed Sarra, Vernieri Claudio
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
Jan 1, 2022Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
Jan 1, 2022J Immunother Cancer 2022; 10
van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Med 2021; 11:332-339.
Dec 17, 2021What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Dec 17, 2021Cancer Med 2021; 11:332-339
Pizzamiglio Sara, Huober Jens, Ellard Susan L, Rimm David L, Gombos Andrea, Daidone Maria Grazia, Verderio Paolo, Tagliabue Elda, Di Cosimo Serena, Nuciforo Paolo, Bajji Mohammed, Cosentino Giulia, Ciniselli Chiara M, De Cecco Loris, Cataldo Alessandra, Plantamura Ilaria, Triulzi Tiziana, El-Abed Sarra, Wang Yingbo, Iorio Marilena V
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Vathiotis I, Kim S, Harbeck N, Gomez H, Shafi S, Syrigos K, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Di Cosimo S, Huober J, Nuciforo P, Moutafi M, Divakar P, Aung T, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Rimm D. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clin Cancer Res 2021
Aug 31, 2021Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Aug 31, 2021Clin Cancer Res 2021
Vathiotis Ioannis A, Kim Sung-Bae, Harbeck Nadia, Gomez Henry, Shafi Saba, Syrigos Konstantinos N, Fountzilas George, Sotiriou Christos, Pusztai Lajos, Warren Sarah, Di Cosimo Serena, Huober Jens, Nuciforo Paolo, Moutafi Myrto K, Divakar Prajan, Aung Thazin Nwe, Qing Tao, Fernandez Aileen, Yaghoobi Vesal, El-Abed Sarra, Wang Yingbo, Guillaume Sébastien, Rimm David L
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
Jul 28, 2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Jul 28, 2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos